Home
Site Map
About Roche
Contact Us
Help
Clinical. Credible. Convenient.
Not a Member?
Log In
Forgot Password?
Instant Access Code
Sign Up
»
E-mail:
Password:
Code:
Remember Me
Log In
»
Go
»
Main Menu
Hepatology Home
News
Clinical Trials
Education
Product Information
PEGASYS (Peginterferon alfa-2a)
Publications
Resources
More Therapeutic Areas
Select an Area
HIV
Influenza
Oncology
Osteoporosis
Rheumatoid Arthritis
More Roche Product Info
Select a Product
Boniva
Fuzeon
Kytril
Invirase
Pegasys
Tamiflu
Xeloda
Other Roche Products
Meeting Calendar
Select a link below to view details.
July 2008
S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Tell us what you think »
Search RocheExchange
Please use TWO or more words to qualify your search.
Example: What is the name of the comprehensive Roche patient support service?
Search
»
Hepatology Publications
Download Acrobat Reader »
Peginterferon Allfa 2a
Other Publications
Publication Search
Display by:
Publication date
Author
Alphabetical by Publication Title
Next »
Hornberger J
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
Journal of Clinical Virology 2006 36(): 283 - 291
Howell C
Peginterferon alfa-2a and Ribavirin for Chronic Hepatitis C Genotype 1 Infections in Black Patients: Safety, Tolerability and Impact on Sustained Virologic Response
Journal of viral hepatitis 2006 13(): 371 - 376
Conjeevaram HS
Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients with Chronic Hepatitis C Genotype 1
Gastroenterology 2006 131(): 470 - 477
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
Peginterferon-alpha2a, lamivudine and the combination for HBeAG-positive chronic hepatitis B
N Engl J Med 2005 352(26): 2682 - 2695
Rodriguez-Torres M
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Antimicrobial agents and chemotherapy 2005 49(): 3997 - 4008
Inati A
Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
British journal of haematology 2005 130(): 644 - 646
Juarez-Navarro A, Vera-de-Leon L, Navarro JM
Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-α2a plus ribavirin in chronic hepatitis C infection
Methods Find Exp Clin Pharmacol. 2005 27(5): 317 - 322
Khalili M, Bernstein D, Lentz E
Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection: Partially blinded, randomized multicenter trial.
Dig Dis Sci. 2005 50(6): 1148 - 1155
Hassanien TI, Cooksley W, Sulkowski M
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
Journal of Hepatology. 2004 40(): 675 - 681
Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
AIDS. 2004 18(13): F21 - 25
Next »